

Nivolumab CheckMate 067

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life




No QoL benefit

Serious and disabling adverse effects



Other adjustments



Long term plateau in the survival curve

Nivolumab CheckMate 067

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response


NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers
Therapeutic Indication: Monotherapy for the treatment of advanced melanoma in adults and adolescents 12 years of age and older*
Experimental Arm: Nivolumab
Control Arm: Ipilimumab

